Summary of Purpose
The purpose of this study is to compile a registry of patients with Fabry disease, an inherited metabolic disorder. In this disease, an enzyme called a-galactosidase A, which normally breaks down a lipid (fatty substance) called globotriaosylceramide (Gb3), is missing or does not function properly. As a result, Gb3 accumulates, causing problems with the kidneys, heart, nerves, and blood vessels. It is not known...Read More →
The following dates are available for this trial. Trial information last updated on 30 June 2017.
|13 Feb 2003||15 Feb 2003||Unavailable||3 Mar 2008||3 Mar 2008||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|